Power of Performance

Capturing the Magic of the Biotech Sector using Disciplined Systematic Investing

Prudent Biotech - Performance

||| Prudence * Patience * Performance |||


Prudent Biotech - Monthly Performance - 2022 ~ GraycellAdvisors.com

plot of month end values



Prudent Biotech - Monthly Performance - 2021 ~ GraycellAdvisors.com

plot of month end values

Prudent Biotech Published Performance

Prudent Biotech - Performance - 2015-2020 ~ Graycell Advisors

Actual Published Performance

PrudentBiotech.com ~ Biotech Stock Performance - Sharpe and Standard Deviation

Would You Like A FREE Monthly Stock Pick?

A pick from our portfolio delivered to your mailbox for the next 12 months

We value your privacy and would never spam or share the email

2003 to 2022


Building Investment Wealth Over Time


Using Systematic Model Investing For Consistent Performance

And It's Repeatable with Discipline and Patience

Why Wait?

Prudent Biotech - a journey from $10,000 to over $9 million & still going ...

Prudent Biotech - $10,000 Portfolio Performance - 2003 to 2020 ~ Graycell Advisors

Accompanying Notes to Understand Performance Calculation:

  • The Portfolio holds 8 stocks at a time. Any changes to the portfolio (new buys/sells) are typically made once per month, usually towards the end of the month or early in the new month. At times there can be intramonth portfolio updates based on market conditions.
  • The Portfolio can be fully invested, partially invested, or in Cash/Treasury ETF when the market risk is perceived to be very high and unfavorable.
  • No short positions are assumed.
  • No leverage or margin is used in any of our model portfolios.
  • Drawdown is an indicator of the risk of a portfolio based on a certain strategy. It measures the largest drop from peak to bottom in the value of a portfolio before a new peak is achieved.
  • The Sharpe Ratio is the most widely used risk-adjusted return measure. It is calculated by subtracting the risk-free rate (typically US Treasury issues like the 13-week Treasury Bill rate) from the rate of return for a portfolio and dividing the result by the standard deviation of the portfolio returns. Developed by Nobel laureate William Sharpe, the Sharpe ratio reveals whether a portfolio's return over the risk-free rate, called the excess return or Alpha, is due to smart investment decisions or a result of assuming excess risk. This ratio allows for a quick performance comparison between funds and strategies. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance compared to a portfolio with a lower Sharpe ratio.
  • Standard Deviation (SD) measures the dispersion or volatility of returns
  • Commissions, fees, taxes, etc. have been ignored in the above computations.
  • The performance numbers are deemed to be hypothetical because they are based on unaduited backtesting and no trades were actually executed in a brokerage account.
  • The cumulative performance chart shows values at the end of the period and is not a continuous running chart, which makes it appear smoothed. Between the periods there could have been dips, even though the portfolio grew for the period.
  • The backtested performance of Prudent Biotech Portfolio is from 2003 till end of 2015. Thereafter, since January 2016, the newsletter was published for subscribers and its actual performance is used to continue calculating the cumulative performance.
  • The performance is unaudited and presented for illustrative purposes only.
  • No representation is being made that a subscriber will or is likely to achieve profits or losses similar to those shown.
  • Historical performance for all periods can vary when we Revise, Update, and Change models. We will not update the website or inform subscribers of such changes due to model modifications.
  • Past performance is not a guarantee of future results. There is always a possibility of significant or complete losses in the equity markets. Future volatility can be much more and returns much less than historical results.
  • Material provided here is only for general informational and illustrative purposes, and is believed to be accurate but not guaranteed. Only you can determine its suitability to your financial objectives and risk profile.

Graycell Advisors, and its affiliates, officers, employees, families, and all other related parties, collectively referred to as ‘Graycell’ and/or ‘we,’ is a publisher of financial information, such as the Prudent Biotech newsletter. Historical performance figures provided are hypothetical, unaudited and prepared by us, based on our proprietary analysis and system performance, back-tested over an extended period of time. The performance results obtained are intended for illustrative purposes only. Past performance is not indicative of future results, which may vary. All stock and related investments have a degree of risk, which can result in significant or total loss. In addition, biotech sector is characterized by much higher risk and volatility than the general stock market. Information contained herein does not constitute a personal recommendation or takes into account the particular investment objectives, financial situations, or needs of individual investors. If you decide to invest in any of the stocks of the companies mentioned in the newsletters, samples, alerts, etc., sent to you or available on our websites, you can and may lose some or all of your investment. You alone are responsible for your own investment decisions. We are not liable nor do we assume any responsibility for losses incurred as a result of any information provided or not provided or not made available in a timely manner, herein or on our website or using any other medium.  We also cannot guarantee the accuracy and completeness of any information furnished by us. Graycell is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. We may or may not already have existing positions in the stocks mentioned in our reports. Our models are proprietary and/or licensed, and can be changed or revised based on our discretion at any time without any notification. Subscribers and investors should always conduct their own due diligence with any potential investment, and consider obtaining professional advice before making an investment decision.